
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : XW003
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of XW003 Injection in Chinese Adolescents with Obesity
Details : XW003 is a Peptide drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Obesity.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
August 27, 2025
Lead Product(s) : XW003
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : XW003
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Comparison of XW003 & Semaglutide Injection in Chinese Adults with Obesity
Details : XW003 is a Peptide drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Obesity.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
July 18, 2025
Lead Product(s) : XW003
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ecnoglutide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I
Sponsor : Verdiva Bio
Deal Size : $2,470.0 million
Deal Type : Licensing Agreement
Sciwind Biosciences Signs Licensing Agreement for Metabolic Disease Portfolio
Details : Under the licensing agreement, Sciwind has granted Verdiva the exclusive global rights to develop and commercialize the partnered programs, which includes XW004 (ecnoglutide) outside of greater China.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : $70.0 million
January 10, 2025
Lead Product(s) : Ecnoglutide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Sponsor : Verdiva Bio
Deal Size : $2,470.0 million
Deal Type : Licensing Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ecnoglutide
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : HK inno.N
Deal Size : $56.0 million
Deal Type : Licensing Agreement
Sciwind Biosciences & HK inno.N ink $56 M Deal to Treat Metabolic Diseases in Korea
Details : HK inno.N gains exclusive rights for XW003 (ecnoglutide), a GLP-1 analog, in Korea; Sciwind retains rights in other global markets.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Undisclosed
May 07, 2024
Lead Product(s) : Ecnoglutide
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : HK inno.N
Deal Size : $56.0 million
Deal Type : Licensing Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : XW003
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Drug-Drug Interaction Study Between XW003 and Metformin, Warfarin, Rosuvastatin or Digoxin
Details : XW003 is a Peptide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
March 28, 2024
Lead Product(s) : XW003
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ecnoglutide
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Sciwind Biosciences Announces Positive Phase 1 Trial Results of XW004
Details : XW004 (ecnoglutide) is a long-acting, cAMP signaling biased, glucagon-like peptide-1 (GLP-1) analog. It is under phase 1 clinical development for the treatment of type 2 diabetes and obesity.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
January 23, 2024
Lead Product(s) : Ecnoglutide
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ecnoglutide
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Sciwind Announces Positive Phase 3 Results for Ecnoglutide in Type 2 Diabetes
Details : XW003 (ecnoglutide) is a long-acting GLP-1 analogue in phase 3 trials for improved biological activity in treating type 2 diabetes.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
January 02, 2024
Lead Product(s) : Ecnoglutide
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ecnoglutide
Therapeutic Area : Undisclosed
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase 3 Study to Evaluate the Efficacy of XW003 in Adults With Overweight or Obesity
Details : Ecnoglutide is a Peptide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
April 14, 2023
Lead Product(s) : Ecnoglutide
Therapeutic Area : Undisclosed
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : XW001
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study To Evaluate the Safety of XW001 Inhalation in Children With RSV
Details : XW001 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Respiratory Syncytial Virus Infections.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 22, 2023
Lead Product(s) : XW001
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ecnoglutide
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : XW003 (ecnoglutide) is a novel, biased long-acting GLP-1 peptide analogue optimized for improved biological activity. GLP-1 analogs are effective therapies in managing type 2 diabetes, obesity, and have demonstrated clinical potential as a treatment for ...
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
January 30, 2023
Lead Product(s) : Ecnoglutide
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
